Prostate cancer screening  

Oleh:

Braillon, Alain ; Dubois, Gérard

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: British Medical Journal (keterangan: ada di Proquest) vol. 335 no. 7632 (Dec. 2007), page 1225.

Ketersediaan

Perpustakaan FK Nomor Panggil: B16.K.2007.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Unacceptable in the under 50s. Lane et al report the feasibility of testing for prostate cancer in men aged 45-49.1 Screening for prostate cancer in men older than 50 is hardly acceptable because overdiagnosis is obvious and the impact on mortality remains unproved despite the findings of numerous trials in the past 15 years. Of 19 major medical organisations worldwide, only the American Cancer Society and the French and American urological associations recommend screening men for prostate cancer with annual measurement of prostate specific antigen (PSA).2 Therefore, in addition to wasting resources, the paper by Lane et al will be used to promote screening.1 In France 36% of men underwent prostate cancer screening (unproved and not organised), whereas only 25% underwent colorectal cancer screening (proved benefit on mortality and organised).3 The only demonstrated effect of prostate cancer screening is a 5-10% biopsy rate in the screened population, with a risk of septicaemia and haemorrhage. Plus, . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali